Tema GLP-1 Obesity & Cardiometabolic ETF
ALTAR
Score™
1.2% info Recommen-
dation
AVOID
2025E    2026E
P/E
ratio
46.5x P/Sales
ratio
2.6x
P/BV
ratio
5.7x Div.
yield
1.4%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
The Tema GLP-1 Obesity & Cardiometabolic ETF seeks to provide investors with exposure to companies that are focused on developing treatments and solutions for obesity and cardiometabolic conditions.

FUND BASICS
Category US Equities
Fund Sponsor Tema
Website temaetfs.com/hrts
Inception date Nov 20, 2023
Assets (mns) $54
Currency USD
Expense ratio 75 bp
Distributions

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian
Weighting
Index replication
Uses derivatives No
Options available Yes

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 42
Wgt avg mkt cap (mns) $198,051
Large cap (>$10bn) 74.8%
Mid cap ($2-10bn) 14.3%
Small cap (<$2bn) 6.9%
Developed mkts 100.0%
Emerging mkts 0.0%

TOP TEN HOLDINGS
ELI LILLY & CO 9.4 %
ABBOTT LABORATORIES 4.7 %
ASTRAZENECA PLC 4.3 %
NOVO NORDISK A/S-B 4.2 %
ROCHE HOLDINGS LTD-SPONS ADR 4.0 %
BOSTON SCIENTIFIC CORP 3.7 %
UNITEDHEALTH GROUP INC 3.7 %
VERTEX PHARMACEUTICALS INC 3.3 %
GILEAD SCIENCES INC 3.2 %
NOVARTIS AG 3.2 %
Total 43.6 %

TOP COUNTRY EXPOSURE
UNITED STATES 72.5 %
DENMARK 7.5 %
SWITZERLAND 7.2 %
BRITAIN 4.4 %
IRELAND 3.0 %
JAPAN 2.5 %